Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam.
This study determined if women with premenstrual dysphoric disorder (PMS) showed impaired mood and performance when they were experiencing their premenstrual symptoms, and if the effects of alprazolam varied as a function of menstrual cycle phase. Under double-blind conditions, the acute effects of placebo and alprazolam (0.25, 0.50, 0.75 mg) were tested during both luteal and follicular phases. Women with confirmed PMS experienced substantial changes in mood as a function of menstrual cycle phase. However, under controlled laboratory conditions, acute doses of alprazolam did not improve negative premenstrual mood, but rather increased negative mood in the follicular phase. Alprazolam impaired task performance, although this impairment was generally similar in both phases when baseline phase differences were taken into consideration. Consistent with the failure of alprazolam to improve mood premenstrually, subjective measures indicative of abuse liability were not increased following alprazolam. Taken together, these data suggest that acute administration of alprazolam doses are not clinically useful for the treatment of PMS.
Evans
S M
SM
New York State Psychiatric Institute, NY 10032, USA. se18@columbia.edu
Haney
M
M
Levin
F R
FR
Foltin
R W
RW
Fischman
M W
MW
D000328:Adult; D000339:Affect / Q000187:drug effects / Q000502:physiology*; D000525:Alprazolam / Q000009:adverse effects / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008568:Memory / Q000187:drug effects; D011293:Premenstrual Syndrome / Q000188:drug therapy* / Q000523:psychology*; D011569:Psychiatric Status Rating Scales; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology*; D011795:Surveys and Questionnaires
D014151:Anti-Anxiety Agents; D000525:Alprazolam